Scarica l'app Stockscreener
5.47
3.36%
-0.19
Dopo l'orario di chiusura:
5.47
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SLDB Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$5.66
Aprire:
$5.64
Volume 24 ore:
902.06K
Relative Volume:
0.87
Capitalizzazione di mercato:
$426.17M
Reddito:
$14.79M
Utile/perdita netta:
$-102.44M
Rapporto P/E:
-1.7993
EPS:
-3.04
Flusso di cassa netto:
$-91.73M
1 W Prestazione:
+3.40%
1M Prestazione:
-6.01%
6M Prestazione:
-1.97%
1 anno Prestazione:
+68.31%
Intervallo 1D:
$5.4099
$5.745
Intervallo di 1 settimana:
$4.92
$5.96
Portata 52W:
$2.41
$7.37
Solid Biosciences Inc Stock (SLDB) Company Profile
Nome
Solid Biosciences Inc
Settore
Industria
Telefono
617-337-4680
Indirizzo
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Confronta SLDB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
5.47 | 440.97M | 14.79M | -102.44M | -91.73M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-04 | Iniziato | Needham | Buy |
| 2025-06-26 | Iniziato | Citigroup | Buy |
| 2025-01-08 | Iniziato | Truist | Buy |
| 2024-12-13 | Iniziato | Wedbush | Outperform |
| 2024-12-10 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-07-15 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-06-24 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-05-31 | Ripresa | Piper Sandler | Overweight |
| 2024-03-28 | Iniziato | William Blair | Outperform |
| 2024-03-15 | Iniziato | Citigroup | Buy |
| 2024-03-14 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-12-08 | Iniziato | H.C. Wainwright | Buy |
| 2021-07-12 | Iniziato | Piper Sandler | Neutral |
| 2021-05-27 | Iniziato | Jefferies | Buy |
| 2021-03-16 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-09 | Iniziato | Barclays | Overweight |
| 2021-01-08 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2020-07-28 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-05-07 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-10-11 | Iniziato | Evercore ISI | Outperform |
| 2019-08-29 | Downgrade | Citigroup | Neutral → Sell |
| 2019-08-19 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-08-16 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2019-05-14 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2019-05-14 | Downgrade | Goldman | Neutral → Sell |
| 2019-02-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2019-02-08 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2018-11-06 | Iniziato | Citigroup | Sell |
| 2018-09-06 | Iniziato | Credit Suisse | Neutral |
Mostra tutto
Solid Biosciences Inc Borsa (SLDB) Ultime notizie
Aug Rallies: Is ITRI stock undervalued right now2025 Breakouts & Breakdowns & Consistent Growth Equity Picks - baoquankhu1.vn
Risk Recap: Whats the beta of Solid Biosciences Inc stockJuly 2025 Institutional & Community Verified Watchlist Alerts - baoquankhu1.vn
Phase 1b Trial for Solid Biosciences’ Friedreich Ataxia Gene Therapy SGT-212 Doses First Patient - NeurologyLive
Solid Biosciences director Ilan Ganot sells $447 in stock - MSN
Solid Bio rises as Duchenne study gets fully enrolled - MSN
JPM26: Solid Biosciences banks on its AAV capsid to catalyse gene therapy success - Pharmaceutical Technology
FOMO Trade: Does Solid Biosciences Inc offer margin of safetyQuarterly Profit Summary & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Solid Biosciences (SLDB) Completes Enrollment in Key Duchenne St - GuruFocus
Needham Reiterates Buy Rating on SLDB with Price Target of $16.0 - GuruFocus
Needham & Company LLC Reiterates "Buy" Rating for Solid Biosciences (NASDAQ:SLDB) - MarketBeat
Solid Bio fully enrolls Duchenne study for lead drug (SLDB) - Seeking Alpha
Solid Biosciences advances gene therapy trials for rare diseases By Investing.com - Investing.com Nigeria
Solid Biosciences (SLDB) Completes Enrollment for SGT-003 Clinical Trial - Intellectia AI
Solid Biosciences (NASDAQ:SLDB) CFO Kevin Tan Sells 5,704 Shares - MarketBeat
Solid Biosciences advances gene therapy trials for rare diseases - Investing.com
Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101 - The Manila Times
Rare disease gene trials grow as Solid Biosciences inks 50+ capsid pacts - Stock Titan
Solid Biosciences doses first participant in Friedreich’s ataxia trial By Investing.com - Investing.com Nigeria
Solid Biosciences receives FDA orphan drug designation for FA therapy By Investing.com - Investing.com Nigeria
Solid Biosciences Gets Orphan Drug Label for SGT-212 to Treat Friedreich's Ataxia - marketscreener.com
SLDB Gains FDA Orphan Drug Designation for SGT-212 in Treating F - GuruFocus
Solid Biosciences receives FDA orphan drug designation for FA therapy - Investing.com
Solid Biosciences Announces FDA Designations for SGT-212 and Completion of First Dosing in Phase 1b FALCON Trial for Friedreich’s Ataxia - Quiver Quantitative
Solid Biosciences receives FDA orphan drug designation for SGT-212 dual-route gene therapy - marketscreener.com
Solid Biosciences Receives FDA Orphan Drug Designation for - GlobeNewswire
Solid Biosciences (SLDB) Begins Dosing in FALCON Trial for SGT-2 - GuruFocus
Solid Biosciences doses first participant in Friedreich’s ataxia trial - Investing.com
Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia - The Manila Times
Solid Biosciences Doses First Participant in First-In-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia - marketscreener.com
Can Solid Biosciences Inc. stock rebound after recent weaknessWeekly Trading Summary & Real-Time Price Movement Reports - Улправда
Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Solid Biosciences (NASDAQ:SLDB) Shares Down 2.2%Here's What Happened - MarketBeat
Solid Biosciences reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Why one new Solid Biosciences hire is getting 7,000 stock units - Stock Titan
Published on: 2026-01-01 04:47:43 - moha.gov.vn
Aug Reactions: Is Solid Biosciences Inc stock a buy before product launches2025 AllTime Highs & Risk Controlled Stock Pick Alerts - moha.gov.vn
Is Solid Biosciences Inc. stock a buy before product launchesJuly 2025 Setups & Smart Investment Allocation Tips - DonanımHaber
Cartography Biosciences’ CBI-1214 gains IND clearance - BioWorld MedTech
Update Report: Is Solid Biosciences Inc. stock a bargain at current levels2025 Performance Recap & Long-Term Investment Growth Plans - Улправда
Solid Biosciences stock rating reiterated at Market Outperform by Citizens - Investing.com Australia
Gene Therapy Milestones And Collaborations Keep Solid Biosciences In Focus - RTTNews
Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services - The Manila Times
Solid Biosciences (SLDB) Sees Duchenne Screening Advancement in US - GuruFocus
Solid Biosciences stock rises after Duchenne added to newborn screening list - Investing.com
Solid Biosciences Supports Duchenne Muscular Dystrophy Inclusion in U.S. Newborn Screening Recommendations - Quiver Quantitative
U.S. newborns will now be screened for Duchenne muscular dystrophy - Stock Titan
Solid Biosciences (SLDB) Gains Attention with Duchenne Muscular Dystrophy Inclusion - GuruFocus
Sarepta's Elevidys Safety Concerns Open Major Opportunity for Solid Biosciences' (SLDB) SGT-003 in Duchenne Therapy - Finviz
Solid Biosciences Inc Azioni (SLDB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.73%
0.92%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):